Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension
2023; Massachusetts Medical Society; Volume: 389; Issue: 3 Linguagem: Inglês
10.1056/nejmoa2208391
ISSN1533-4406
AutoresAkshay S. Desai, David J. Webb, Jörg Täubel, Sarah Casey, Yansong Cheng, Gabriel J. Robbie, Don Foster, Stephen A. Huang, Sean H. Rhyee, Marianne T. Sweetser, George L. Bakris,
Tópico(s)Hormonal Regulation and Hypertension
ResumoAngiotensinogen is the sole precursor of angiotensin peptides and has a key role in the pathogenesis of hypertension. Zilebesiran, an investigational RNA interference therapeutic agent with a prolonged duration of action, inhibits hepatic angiotensinogen synthesis.
Referência(s)